We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
SkyePharma PLC announce that it has agreed with its North American partner Endo Pharmaceuticals (ENDP) to terminate the joint development of Propofol IDD-D, an injectable anesthetic and sedative that was licensed to Endo in December 2002.
As it prepares for the launch of GlaxoSmithKline's beta-blocker Coreg (carvedilol) with a controlled release formulation, drug delivery company Flamel saw its bottom line, in the absence of new partners, shift deep into the red in the first quarter of 2006.
The Debiopharm Group, an independent global drug development company specialising in oncology and serious medical conditions, and TcLand S.A., a French biopharmaceutical company specialising in the development of immunological biomarkers and therapeutic molecules to control organ transplant rejection and immune disorders, announced the signature of an exclusive in-licensing option agreement for the development of the fusion protein sc28AT, a CD28 antagonist in preclinical development.
Approximately $55 million is required annually to continue Kenya's comprehensive HIV/AIDS vaccine program, according to the locally based International Aids Vaccine Initiative (IAVI).
Younger women with breast cancer may be helped with better tailoring of chemotherapy regimens, according to a Canadian study published in the New England Journal of Medicine.
German drugmaker Jerini and U.S.-based Baxter have reported progress in their collaborative research program to develop a non-intravenous therapy for the treatment of hemophilia.
Pathogen Removal and Diagnostic Technologies Inc. (PRDT), a joint venture between ProMetic Life Sciences Inc. (TSX:PLI) and the American Red Cross, today announced that it has signed a definitive license agreement with MacoPharma.
Swiss Medica, Inc. is pleased to announce that third quarter revenues for the three months ended March 31, 2006, grew 8% over Q1 2005 quarterly results to US$1.22 million.